Evidence map›Paper›PMID 42180332›Full record

ArticlemedRxiv : the preprint server for health sciences2026

A phenotype-to-mechanism framework links phenome-wide comorbidity architecture to molecular mechanisms and therapeutic discovery in complex diseases.

Wei-Ting Wang, Manqi Zhou, Jie Tong, Meng-Ju Lin, Alison Ke, Meihan Wei, Zhenxing Xu, Hansen Tai, Aarthi Parvathaneni, Khyla T Hill and 6 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wei-Ting WangDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Manqi ZhouDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Jie TongThe Hansjörg Wyss Department of Plastic Surgery, New York University Grossman School of Medicine, New York, NY, USA.
Meng-Ju LinThe Hansjörg Wyss Department of Plastic Surgery, New York University Grossman School of Medicine, New York, NY, USA.
Alison KeDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Meihan WeiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Zhenxing XuDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0001-9515-523X
Hansen TaiIsrael Englander Department of Dermatology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Aarthi ParvathaneniIsrael Englander Department of Dermatology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Khyla T HillIsrael Englander Department of Dermatology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Steven R CohenIsrael Englander Department of Dermatology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
Lynn PetukhovaRonald O. Perelman Department of Dermatology, Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-1573-1653
Ernest S ChiuThe Hansjörg Wyss Department of Plastic Surgery, New York University Grossman School of Medicine, New York, NY, USA.
Fei WangDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Catherine P LuThe Hansjörg Wyss Department of Plastic Surgery, New York University Grossman School of Medicine, New York, NY, USA.
Chang SuDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.

Funding

Progression Subtyping and Drug Target Identification for Parkinson's Disease with Integrative Machine LearningR01NS140142 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Chang Su · 2025 to 2026
$1.3M
NINDS NIH HHS R01 NS140142
6 · The paper itself

Abstract

Complex human diseases exhibit substantial clinical heterogeneity driven by poorly understood molecular mechanisms, while many also lack sufficient molecular and omics data for mechanistic investigation, hindering therapeutic development. We introduce PiMInfer, a "phenotype-to-mechanism" framework that leveraged largely available real-world clinical data-based deep phenotypic characterizations with a biomedical knowledge graph approach to resolve disease clinical heterogeneity into phenotype-informed molecular modules, thereby accelerating therapeutic target discovery. We applied PiMInfer to investigate Hidradenitis Suppurativa (HS), an autoimmune skin disease with poorly understood pathogenesis and limited treatment options. PiMInfer identified a coherent, phenotype-informed HS gene module (PiHSM) and functional endotypes, which were validated using multimodal evidence.

Identifiers

PMID42180332
PMCPMC13193042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.